JPMorgan analyst Andrea Teixeira upgraded Procter & Gamble to Overweight from Neutral with a price target of $155, up from $150. The analyst now thinks consensus estimates are low into the back end of 2023, creating a more positive setup for the shares. Investors will grow back to appreciate the earnings compounding ahead and relative resilience of names like Procter & Gamble, the analyst tells investors in a research note. The firm says capacity constraints in the company’s key divisions including fabric care and feminine care will abate this year.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PG:
- Procter & Gamble upgraded to Buy from Neutral at UBS
- Procter & Gamble initiated with a Buy at Citi
- Procter & Gamble’s (NYSE:PG) Robust Brand Portfolio to Sustain Strong Results
- Procter & Gamble (NYSE:PG): A Wonderful Recession-Prep Stock
- Procter & Gamble call volume above normal and directionally bullish
Questions or Comments about the article? Write to editor@tipranks.com